Sunitinib
- Generic Name
- Sunitinib
- Brand Names
- Sutent, Sunitinib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C22H27FN4O2
- CAS Number
- 557795-19-4
- Unique Ingredient Identifier
- V99T50803M
- Background
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.
- Indication
Sunitinib is indicated for the following conditions:
- Associated Conditions
- Gastrointestinal Stromal Tumor (GIST), Renal Cell Carcinoma (RCC), Renal Cell Carcinoma Recurrent, Unresectable, locally advanced Progressive Neuroendocrine Tumors of pancreatic origin, Unresectable, metastatic Progressive Neuroendocrine Tumors of pancreatic origin
- Associated Therapies
- -
Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC Patients
- First Posted Date
- 2013-09-04
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 77
- Registration Number
- NCT01934452
- Locations
- 🇫🇷
CHRU HOTEL DIEU - Service Urologie, Angers Cedex, France
🇫🇷CHU Strasbourg, Strasbourg, Cedex, France
🇫🇷C.H.U Morvan, Brest, France
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer
- First Posted Date
- 2013-04-18
- Last Posted Date
- 2021-02-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 157
- Registration Number
- NCT01835158
- Locations
- 🇺🇸
Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States
🇺🇸Toledo Radiation Oncology at Northwest Ohio Onocolgy Center, Maumee, Ohio, United States
🇺🇸Licking Memorial Hospital, Newark, Ohio, United States
Sunitinib in Never-Smokers With Lung Adenocarcinoma
- First Posted Date
- 2013-04-11
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 13
- Registration Number
- NCT01829217
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Isreal Deaconess Medical Center, Boston, Massachusetts, United States
A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-04-11
- Last Posted Date
- 2018-05-03
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT01829841
- Locations
- 🇨🇳
Cancer Institute and Hospital Chinese Academy of Medical Sciences, Beijing, China
Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma
- First Posted Date
- 2013-04-05
- Last Posted Date
- 2018-07-18
- Lead Sponsor
- Cathay General Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT01824615
- Locations
- 🇨🇳
Cathay General Hospital, Taipei, Taiwan
Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2013-03-04
- Last Posted Date
- 2016-06-22
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 80
- Registration Number
- NCT01803503
- Locations
- 🇸🇬
National University Hospital, Singapore, Singapore
Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-02-06
- Last Posted Date
- 2017-10-02
- Lead Sponsor
- Associació per a la Recerca Oncologica, Spain
- Target Recruit Count
- 41
- Registration Number
- NCT01784978
- Locations
- 🇫🇷
Hopital Bordeaux University, Bordeaux, France
🇬🇷ALEXANDRA General Hospital of Athens, Athens, Greece
🇪🇸Hospital Marqués de Valdecilla, Santander, Cantabria, Spain
The Influence of Phenotype, Grapefruit Juice and Orange Juice on the Pharmacokinetics of Sunitinib in Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2012-12-06
- Last Posted Date
- 2012-12-19
- Lead Sponsor
- Leiden University Medical Center
- Target Recruit Count
- 15
- Registration Number
- NCT01743300
Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-12-04
- Last Posted Date
- 2018-12-06
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 13
- Registration Number
- NCT01740154
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors
- Conditions
- Interventions
- First Posted Date
- 2012-11-22
- Last Posted Date
- 2017-01-31
- Target Recruit Count
- 44
- Registration Number
- NCT01731925
- Locations
- 🇧🇪
UZ Leuven, Leuven, Belgium
🇫🇷Hôpital Henri Mondor, Créteil, France
🇧🇪ULB Erasme, Brussels, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.